Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Where Merck KGAA’s Pipeline Stands

Executive Summary

Pipeline review resulted in new focus and products with high value, exec explains.

You may also be interested in...



On The Threshold Of The Tumor Microenvironment

Threshold Pharmaceuticals’ lead compound from its hypoxia-activated prodrug platform, TH-302, is partnered with Merck KGaA on one Phase III program and in internal development for another Phase III.

Merck KGaA Finds R&D Nuggets: Plans Further Atacicept Studies In Lupus

A discussion with internal and external experts restarts clinical development of atacicept for lupus after a two-year hiatus.

Merck Serono Is Hoping It Pays To Plan Ahead With New Phase III Trial For Tecemotide

Merck Serono will conduct a second Phase III study of lung cancer vaccine tecemotide in patients treated concurrently with chemotherapy and radiation. The START trial, which also dosed patients receiving sequential therapy, failed but the predefined, concurrently treated subgroup showed greater median overall survival compared to placebo.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

PS056807

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel